Synopsis: Manipal Health Enterprises’ ₹9,273.64 crore IPO opens from July 29–31, 2026, with proceeds earmarked for debt repayment, stake acquisition, and growth. Backed by strong financials and a leading hospital network, the IPO appears fairly priced, making it suitable for long-term healthcare-focused investors.
Manipal Health Enterprises IPO has launched its Initial Public Offering (IPO) today, with the proceeds aimed at supporting growth initiatives, debt repayment, and business expansion. The IPO is a book-built issue worth Rs. 9,273.64 crore. The issue comprises a fresh issue of 13.56 crore shares, aggregating to Rs. 7,998.43 crore, and an offer for sale (OFS) of 2.16 crore shares, aggregating to Rs. 1,275.22 crore.
Manipal Health Enterprises IPO will open for subscription on July 29, 2026, and close on July 31, 2026. The allotment for the IPO is expected to be finalized on August 3, 2026. The shares are scheduled to be listed on both NSE and BSE, with a tentative listing date of August 5, 2026. Manipal Health Enterprises IPO is set to issue a price band at Rs. 560 to Rs. 590 per share.
GMP of Manipal Health Enterprises IPO
As of July 28th, 2026, the shares of Manipal Health Enterprises Ltd in the grey market were trading at a 1.69 percent premium. The shares in the Grey Market traded at Rs. 600. This gives it a premium of Rs. 10 per share over the cap price of Rs. 590.
Overview of Manipal Health Enterprises IPO
Manipal Health Enterprises Limited, incorporated in 2010, is a leading healthcare service provider operating a network of multi-specialty hospitals, clinics, and diagnostic centres across India. It is part of the Manipal Group, founded by T. M. A. Pai.
The company provides a wide range of healthcare services, including tertiary and quaternary care, organ transplants, oncology, cardiology, neurology, orthopaedics, and preventive healthcare. Its hospitals are supported by advanced medical technology and experienced healthcare professionals.
Manipal Health focuses on delivering patient-centric care and improving healthcare accessibility through strategic acquisitions, partnerships, investments in medical infrastructure, and digital health initiatives.
As of September 30, 2025, the company operated 38 hospitals (48 hospitals on a pro forma basis) with 10,761 licensed beds (12,367 licensed beds on a pro forma basis), along with 17 clinics across India, strengthening its position as one of the country’s leading healthcare providers.
Promoters of Manipal Health Enterprises IPO
The promoters of Manipal Health Enterprises Limited, including Ranjan Ramdas Pai, Manipal Global Health Services, MEMG International Ltd, Kangto Investments Pte. Ltd., Imperius Healthcare Investments Pte. Ltd., and Kabru Investments Pte. Ltd., bring extensive expertise in healthcare management, hospital operations, strategic investments, and expansion of medical infrastructure.
Their strong leadership and deep understanding of healthcare delivery, patient-centric services, clinical excellence, and large-scale healthcare network development have been instrumental in establishing Manipal Health as a leading multi-specialty healthcare provider in India.
Offer for Sale (OFS)
The Offer for Sale (OFS) in the Manipal Health Enterprises IPO comprises equity shares offered by existing shareholders, including Imperius Healthcare Investments Pte. Ltd., Manipal Education and Medical Group India Private Limited, TPG SG Magazine Pte. Ltd., and other investors.
Under the OFS, Imperius Healthcare Investments Pte. Ltd. will offer up to 10,808,861 equity shares, while Manipal Education and Medical Group India Private Limited will offer up to 6,792,002 equity shares. Other selling shareholders include TPG SG Magazine Pte. Ltd., Seventy Second Investment Company LLC, Ammar Sdn Bhd, Novo Holdings Invest Asia A/S, and Phoenix Bear Investments, LLC.
Lead Managers of Manipal Health Enterprises
Kotak Mahindra Capital Company Limited, Axis Capital Limited, Goldman Sachs (India) Securities Private Limited, Jefferies India Private Limited, J.P. Morgan India Private Limited, UBS Securities India Private Limited, and DBS Bank India Limited are the Book Running Lead Managers for the IPO, while KFin Technologies Limited is the registrar responsible for managing investor applications, processing allotments, and handling related IPO procedures.
Objectives of the IPO Offer
The objective of the Manipal Health Enterprises IPO is to utilise the net proceeds primarily towards the repayment or prepayment, in full or part, of certain outstanding borrowings and accrued interest thereon availed by its material subsidiary, Manipal Hospitals Private Limited, amounting to Rs. 5,378 crore.
The company also intends to utilise Rs. 574 crore towards the acquisition of a minority stake in its step-down subsidiary, Sahyadri Hospitals Private Limited, along with meeting general corporate purposes.
Financial Analysis of Manipal Health Enterprises Ltd
The company has demonstrated a strong financial performance over the years, with total income increasing from Rs. 4,927.57 crore in FY23 to Rs. 6,265.17 crore in FY24, further rising to Rs. 9,409.12 crore in FY25. The company reported total income of Rs. 5,436.31 crore for the period ended September 30, 2025, reflecting continued business growth.
Profit After Tax (PAT) remained stable during the period, increasing from Rs. 414.20 crore in FY23 to Rs. 533.20 crore in FY24, before reaching Rs. 534.80 crore in FY25. The company reported a PAT of Rs. 319.47 crore for the six months ended September 30, 2025.
Manipal Health Enterprises vs Peers
The company has been compared with listed industry peers, including Apollo Hospitals Enterprise Ltd, Fortis Healthcare Ltd, and Max Healthcare Institute Ltd., based on key financial and valuation parameters.
The company reported revenue from operations of Rs. 10,335.75 million, with a basic EPS of Rs. 7.71 and diluted EPS of Rs. 7.67. Its NAV per share stood at Rs. 72.55, with a Return on Net Worth (RoNW) of 10.57%.
Among peers, Apollo Hospitals reported the highest revenue from operations at Rs. 252,285 million with a P/E ratio of 66.15x, while Fortis Healthcare and Max Healthcare reported revenues of Rs. 91,278.40 million and Rs. 100,650.00 million, respectively. The peer comparison highlights the company’s position within the growing healthcare services sector.
Manipal Health Enterprises Strengths and Weaknesses
Strengths
- India’s largest multispecialty hospital group by bed capacity, with a pan-India presence and leadership across three key regions.
- The only private hospital chain in India with a leadership position in three major metros — Bengaluru, Kolkata, and Pune — supported by a balanced presence across metro and non-metro markets.
- A widely recognized healthcare brand and preferred network for patients, doctors, and healthcare professionals.
- Equipped with advanced infrastructure and medical technology, with a strong focus on clinical excellence and quality patient care.
- Demonstrated track record of delivering industry-leading growth, supported by strong profitability and operational efficiency metrics.
Weakness
- A significant portion of the company’s hospitals and revenue are concentrated in Karnataka, with any operational disruptions, policy changes, or regional challenges potentially impacting business performance.
- The company’s revenue is primarily dependent on inpatient care services; any decline in patient admissions or hospital occupancy rates could adversely affect financial performance.
- A major share of inpatient revenue comes from key specialties such as cardiac sciences, oncology, neurosciences, gastro sciences, orthopaedics, and renal sciences (CONGO-R). Any decline in demand for these specialties may affect growth and profitability.
- A portion of the IPO proceeds will be used for repayment/prepayment of borrowings, including non-convertible debentures issued to DBS Bank Ltd., which has an association with one of the company’s promoters.
- Future acquisitions, strategic investments, partnerships, or alliances may involve integration challenges and could impact the company’s operations and financial performance.
Conclusion
Manipal Health Enterprises IPO provides exposure to a leading healthcare player with a strong hospital network, established brand, and consistent growth. However, regional concentration, dependence on inpatient services, and expansion-related risks remain key concerns.
At the given valuation, the IPO appears fairly priced. It may suit long-term investors looking for healthcare sector growth, while listing gains will depend on market sentiment and grey market trends.
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
